首页> 外文学位 >HER2Delta16: a tumor-specific oncogene that drives tumorigenesis and trastuzumab resistance in HER2+ breast cancer.

【24h】

HER2Delta16: a tumor-specific oncogene that drives tumorigenesis and trastuzumab resistance in HER2+ breast cancer.

机译：HER2Delta16：一种肿瘤特异性癌基因，可驱动HER2 +乳腺癌的肿瘤发生和曲妥珠单抗。

获取原文

获取原文并翻译 | 示例

页面导航

著录项
相似文献
相关主题

著录项

作者
Huynh, Felicia C.;
展开▼
作者单位

Tulane University School of Science and Engineering.;

展开▼
授予单位 Tulane University School of Science and Engineering.;
学科 Cellular biology.;Oncology.;Molecular biology.
学位 Ph.D.
年度 2015
页码 181 p.
总页数 181
原文格式 PDF
正文语种 eng
中图分类物理化学（理论化学）、化学物理学;
关键词

相似文献

外文文献
中文文献
专利

1. Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. [J] . Wu Y, Amonkar MM, Sherrill BH, Annals of oncology: official journal of the European Society for Medical Oncology . 2011,第12期

机译：拉帕替尼联合曲妥珠单抗与单药拉帕替尼对曲妥珠单抗难治性HER2 +转移性乳腺癌患者生活质量的影响。
2. Trastuzumab emtansine (T-DM1): a novel agent for targeting HER2+ breast cancer. [J] . Burris HA 3rd, Tibbitts J, Holden SN, Clinical breast cancer . 2011,第5期

机译：曲妥单抗Emtansine（T-DM1）：一种针对HER2 +乳腺癌的新型药物。
3. Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer. [J] . Yardley DA, Raefsky E, Castillo R, Clinical breast cancer . 2011,第5期

机译：每周一次新辅助用nab-紫杉醇和卡铂联合贝伐单抗和曲妥珠单抗的II期研究，用于治疗局部晚期HER2 +乳腺癌的妇女。
4. Characterization of endogenous phosphorylation in p130Cas, an anti-estrogen resistance generating protein in human breast cancer. [C] . Giuseppe Infusini, Anthony Makkinje, David H. Perlman, ASMS Conference on Mass Spectrometry and Allied Topics . 2008

机译：P130CAs中内源性磷酸化的表征，人乳腺癌中抗雌激素产生蛋白质。
5. Analysis of Trastuzumab (Tzb) Sensitivity in HER2+ PTEN-Deficient Breast Cancer Using Single Cell RNA-Seq [D] . Do, Jamie. 2020

机译：单细胞RNA-SEQ分析HER2 + PTEN缺乏乳腺癌中的曲妥珠单抗（TZB）敏感性
6. Metformin-induced preferential killing of breast cancer initiating CD44+CD24−/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts [O] . Sílvia Cufí, Bruna Corominas-Faja, Alejandro Vazquez-Martin, 2012

机译：二甲双胍诱导的启动CD44 + CD24- / low细胞乳腺癌的优先杀伤足以克服HER2 +人乳腺癌异种移植物中对曲妥珠单抗的主要耐药性
7. Cost-Utility Analysis of Neoadjuvant Chemotherapy with Pertuzumab, Trastuzumab and Docetaxel in Patients With HER2+ Breast Cancer in Spaincost-Utility Analysis of Neoadjuvant Chemotherapy with Pertuzumab, Trastuzumab and Docetaxel in Patients With HER2+ Breast Cancer in Spain [O] . R Colomer, E Ciruelos, J De la Haba, 2016

机译：西班牙治疗腹膜康氏症患者腹膜癌患者腹膜癌，胸瘤和多西紫杉醇患者腹膜癌患者的新辅助化疗的成本实用性分析

HER2Delta16: a tumor-specific oncogene that drives tumorigenesis and trastuzumab resistance in HER2+ breast cancer.

著录项

相似文献

相关主题

期刊订阅